drugset
drugset / Trial / NCT05688124

A Study of IBI351 in Healthy Subjects

NCT05688124 ↗

Phase 1 Completed 24 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedParallel-groupOpen-labelOther

Summary

This is a randomized, open-label, two-cycle clinical study to evaluate the drug interaction, food effect and pharmacokinetics of IBI351 and esomeprazole in healthy subjects. A total of two cohorts were planned to be enrolled in each cohort. Cohort 1: This cohort investigated the effect of esomeprazole on the pharmacokinetics of IBI351 in healthy subjects. Cohort 2: This cohort investigated the effect of food on the pharmacokinetics of IBI351 in healthy subjects.

Timeline

Start
2023-02-16
Primary completion
2023-10-16
Completion
2023-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule — Oral
Subject IBI351 Small molecule — Oral

Indications

No indication recorded.